Overview
Study information
| Network: | HVTN |
| Grant Affiliation: | NA |
| Strategy: | Combo: Protein & vector vaccines |
| Study Type: | Phase I/II |
| Species: | Human |
| Stage: | Follow up complete |
| Study Start Date: | NA |
| Study Made Public: | NA |
Title
A Phase 1-2 randomized, double-blind, placebo-controlled clinical trial of clade C ALVAC-HIV (vCP2438) and Bivalent subtype C gp120/MF59 in HIV-1 uninfected persons at low risk of HIV infection
Description
HVTN 100 is a Phase I/II clinical trial to evaluate the safety and immunogenicity of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59.
Sign in to see full information about this study and to download study data.
Products
Product info coming soon!Integrated data
No integrated data is available for this study.
Non-integrated data
No non-integrated data is available for this study.